List of Excipients in Branded Drug FLOLAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	FLOLAN	epoprostenol sodium	0173-0517	GLYCINE
GlaxoSmithKline LLC	FLOLAN	epoprostenol sodium	0173-0517	MANNITOL
GlaxoSmithKline LLC	FLOLAN	epoprostenol sodium	0173-0517	SODIUM CHLORIDE

FLOLAN Epoprostenol Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

FLOLAN is an epoprostenol sodium intravenous product for pulmonary arterial hypertension. Its commercial vulnerability is driven less by the active ingredient than by formulation stability, reconstitution, cold-chain requirements, sterile manufacturing, and infusion-device compatibility. The main excipient opportunity is to improve room-temperature stability and simplify preparation without changing epoprostenol delivery, concentration, or clinical use.

Flolan is a small-molecule drug, so biosimilar regulation does not apply. Generic and alternative epoprostenol products can compete through abbreviated new drug applications, formulation differentiation, hospital contracting, and lower handling costs. The strongest commercial position is likely to come from a stable ready-to-use or simplified presentation rather than from a new excipient alone.

What is FLOLAN and how does its formulation work?

Flolan contains epoprostenol sodium, a prostacyclin analogue that produces pulmonary and systemic vasodilation and inhibits platelet aggregation. It is administered by continuous intravenous infusion because epoprostenol has an extremely short plasma half-life, generally measured in minutes [1].

The product is supplied as a sterile lyophilized powder that must be reconstituted before infusion. The formulation uses a strongly alkaline environment to improve epoprostenol stability. The core formulation architecture is:

Component	Function
Epoprostenol sodium	Active pharmaceutical ingredient
Glycine	Bulking and stabilizing excipient
Mannitol	Bulking agent and tonicity modifier
Sodium hydroxide	pH adjustment and alkaline stabilization
Water for injection	Reconstitution and dilution vehicle

The exact quantities, reconstitution instructions, concentrations, storage conditions, and in-use limits are controlled by the approved labeling and manufacturing process. The product’s high-pH formulation is clinically relevant because diluted epoprostenol solutions have limited stability and require controlled handling [1].

Why does Flolan require specialized handling?

Epoprostenol is chemically unstable in aqueous solution. The product therefore depends on:

• Lyophilization to maintain solid-state stability.
• Alkaline pH after reconstitution.
• Controlled dilution.
• Refrigerated storage for many prepared solutions.
• Defined in-use periods.
• Continuous infusion through a dedicated delivery system.

Treatment interruption can cause rapid loss of pharmacologic effect. A formulation change that increases stability, reduces preparation steps, or reduces pump and line-management burden has direct clinical and commercial value.

What excipients are used in Flolan?

The key excipient strategy is conventional rather than novel. Glycine and mannitol support the lyophilized cake and reconstituted solution, while sodium hydroxide establishes the alkaline pH needed for product stability.

Glycine and mannitol

Glycine is widely used in parenteral products as a bulking agent and stabilizer. Mannitol provides bulk and can contribute to tonicity after reconstitution. The combination is suited to a freeze-dried injectable because it can produce a physically acceptable cake and support rapid reconstitution.

A reformulation using a different bulking system would need to address:

• Cake structure and collapse temperature.
• Residual moisture.
• Reconstitution time.
• Particulate formation.
• Osmolality.
• Container closure integrity.
• Chemical degradation of epoprostenol.
• Compatibility with infusion pumps and tubing.

Replacing either glycine or mannitol may create a patentable formulation position, but the regulatory burden is higher than for a manufacturing improvement that preserves the approved composition.

Sodium hydroxide and alkaline pH

Sodium hydroxide is not primarily a buffering excipient in Flolan. It adjusts the formulation to a strongly alkaline pH. The pH must be controlled tightly because epoprostenol degradation is sensitive to the aqueous environment.

A lower-pH formulation could offer handling advantages, but it would require evidence that the alternative pH profile maintains potency, impurity control, sterility, and in-use stability. A buffered system could be commercially attractive if it reduces degradation after dilution, but it could also introduce new risks involving ionic strength, precipitation, adsorption, and compatibility with administration sets.

What formulation patents protect Flolan and epoprostenol products?

The original compound and formulation exclusivity associated with Flolan are no longer the primary commercial barrier. Flolan was approved by the FDA in 1995, and the product has been exposed to generic and alternative epoprostenol competition for many years [2].

The current value is more likely to reside in:

IP category	Commercial relevance
Compound patents	Limited for mature epoprostenol sodium
Lyophilized formulation patents	Potentially relevant to specific excipient ratios, pH, moisture, and stability
Ready-to-use solutions	Potentially relevant to concentration, container, and storage profile
Infusion-device compatibility	Relevant to integrated drug-device presentations
Manufacturing processes	Relevant to sterile fill, lyophilization, impurity control, and yield
Method-of-use patents	Limited value where treatment practice is established
Packaging patents	Relevant to premixed bags, cartridges, and light or oxygen protection

A company pursuing a new product should focus its freedom-to-operate analysis on formulation, concentration, presentation, container closure, manufacturing, and device patents rather than assuming that the active ingredient is proprietary.

When does Flolan lose exclusivity?

Flolan’s original regulatory exclusivity and early patent protection have expired. The product is a mature small-molecule injectable. Current market access therefore depends on approved labeling, manufacturing capability, supply reliability, contracting, and formulation differentiation.

The relevant exclusivity framework is:

Exclusivity type	Flolan position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Expired for the original approval period
Pediatric exclusivity	No current commercial significance
Compound patent exclusivity	Expired or commercially exhausted
Formulation and process protection	May exist for later products or specific presentations
Biosimilar exclusivity	Not applicable
Generic competition	Applicable

Epoprostenol sodium is a small molecule. A competitor generally follows the ANDA pathway rather than the biosimilar pathway. A Paragraph IV certification may be relevant only if an ANDA applicant challenges an unexpired listed patent. For the mature Flolan product, the principal barrier is usually product development and manufacturing execution rather than basic molecule exclusivity [3].

What is the FDA regulatory status of Flolan?

Flolan was approved for intravenous use in pulmonary arterial hypertension. Its clinical use requires continuous infusion and careful preparation. FDA-approved epoprostenol products include Flolan and later products designed to improve stability and handling.

Veletri, another epoprostenol sodium product, was developed with a formulation intended to provide improved stability compared with the original Flolan presentation. Its commercial role demonstrates that excipient and presentation changes can support a differentiated epoprostenol product even after compound exclusivity has expired [4].

The principal regulatory routes are:

• ANDA for a therapeutically equivalent generic where the reference product and product characteristics support the pathway.
• 505(b)(2) NDA for a materially different formulation, presentation, concentration, or administration system.
• Combination-product or device-related review where the drug is integrated with a delivery system.
• Supplemental NDA for post-approval changes to an existing branded product.

A ready-to-use product with a materially different formulation or storage profile may be better suited to a 505(b)(2) strategy than a conventional ANDA, depending on the reference product and the claimed differences.

What commercial opportunities exist for Flolan excipients?

The largest opportunity is not a premium excipient by itself. It is an excipient-enabled product that lowers total treatment friction.

1. Room-temperature-stable formulations

A formulation that remains stable at room temperature for clinically useful periods could reduce refrigeration, preparation errors, and pharmacy handling. This is the highest-value technical target.

Potential approaches include:

• Optimizing glycine-mannitol ratios.
• Adjusting alkaline pH within a safe stability window.
• Evaluating alternative buffering systems.
• Reducing oxygen and light exposure.
• Controlling residual moisture in the lyophilized cake.
• Using protective container closure systems.

The product would need to preserve potency and impurity specifications after reconstitution, dilution, transport, and infusion.

2. Ready-to-use or premixed presentations

Premixed infusion bags, prefilled syringes, cartridges, or pharmacy-ready vials could reduce reconstitution time. These formats would be commercially useful in intensive-care, emergency, and pulmonary hypertension settings.

The main development barriers are:

• Aqueous degradation.
• Adsorption to tubing or container surfaces.
• Extractables and leachables.
• Sterility over the labeled shelf life.
• Pump accuracy.
• Container compatibility.
• Shipping temperature excursions.

A ready-to-use presentation could command a premium if it reduces pharmacy labor and cold-chain dependence.

3. Higher-concentration products

Higher concentrations can reduce infusion volume and may help patients receiving chronic therapy or those with fluid restrictions. The strategy must balance concentration against:

• Local irritation and line compatibility.
• Pump accuracy at low flow rates.
• Precipitation risk.
• Osmolality.
• Dose flexibility.
• Clinical conversion errors.

Concentration-based differentiation may be easier to commercialize in specialty settings where treatment protocols are standardized.

4. Excipient supply and contract manufacturing

Suppliers can target the epoprostenol market with:

• Low-endotoxin glycine and mannitol.
• Parenteral-grade excipients with tight bioburden control.
• Custom premixes for sterile fill.
• Lyophilization cycle development.
• Low-adsorption polymer bags and tubing.
• Container closure systems designed for alkaline solutions.
• Stability-indicating analytical methods.

The value proposition is supply assurance, batch consistency, and regulatory documentation. Price competition is likely for commodity-grade excipients, while validated sterile components and formulation services can retain higher margins.

How strong is the Flolan patent estate?

The basic Flolan patent estate is weak from a current market-exclusivity perspective because the drug is mature and multiple epoprostenol products have entered the market. A new entrant could still create a defensible position around a specific product configuration.

Patent strength is highest where claims combine:

1. A defined epoprostenol concentration.
2. A narrow pH range.
3. Specified glycine and mannitol quantities.
4. A measured stability profile.
5. A particular container or infusion set.
6. A defined temperature excursion period.
7. A clinically useful ready-to-use presentation.

Weak claims would cover broad use of glycine, mannitol, sodium hydroxide, or epoprostenol without a specific technical effect. Those excipients are well established in injectable products, making broad composition claims vulnerable to obviousness and anticipation challenges.

Which companies are challenging or competing with Flolan?

Competition comes from generic epoprostenol products and from differentiated branded epoprostenol presentations. Veletri, associated with Actelion and later Johnson & Johnson, is the most important branded comparator because it addressed stability and handling limitations associated with earlier epoprostenol products [4].

The competitive landscape includes:

Competitor category	Primary advantage
Generic epoprostenol sodium	Lower acquisition cost
Veletri	Improved formulation stability and handling profile
Flolan	Established clinical history and institutional familiarity
Treprostinil products	Longer duration and different administration options
Inhaled prostacyclin products	Avoidance of continuous intravenous infusion in selected patients

Treprostinil is not a generic substitute for epoprostenol. It competes therapeutically but has different pharmacology, administration options, dosing, and clinical protocols.

What generic launch risks exist for Flolan?

Generic launch risk is substantial because the active ingredient is mature and the clinical demand is established. The main risk factors are:

• Price erosion in hospital and specialty-pharmacy contracts.
• Multiple-source supply.
• Switching driven by procurement rather than physician preference.
• Lower barriers to clinical substitution after institutional protocol review.
• Stock-out risk that favors suppliers with reliable manufacturing.
• Limited ability to sustain premium pricing without a handling advantage.

A generic entrant still faces meaningful execution barriers. Epoprostenol requires sterile manufacturing, sensitive stability control, validated reconstitution instructions, and reliable supply. A product that is cheaper but operationally difficult may not displace a stable incumbent.

What patent litigation and Paragraph IV risks affect epoprostenol?

No biosimilar litigation framework applies because epoprostenol is a small molecule. Paragraph IV litigation depends on whether an ANDA applicant identifies an unexpired Orange Book-listed patent for the relevant reference product.

For a mature Flolan strategy, the more material legal risks are likely to involve:

• Later-generation epoprostenol formulations.
• Ready-to-use presentations.
• Stability-enhancing excipient combinations.
• Container and infusion-device systems.
• Manufacturing process claims.
• Method-of-use claims tied to dosing or patient subgroups.

Settlement agreements may affect launch timing where a generic applicant challenges a later formulation patent. The commercial significance of any settlement depends on the patent claims, the reference product, the agreed launch date, and whether the agreement includes supply or licensing terms.

How does Flolan compare with Veletri and treprostinil?

Attribute	Flolan	Veletri	Treprostinil products
Active ingredient	Epoprostenol sodium	Epoprostenol sodium	Treprostinil
Core use	Pulmonary arterial hypertension	Pulmonary arterial hypertension	Pulmonary arterial hypertension
Administration	Continuous IV infusion	Continuous IV infusion	IV, subcutaneous, inhaled, or oral depending on product
Stability strategy	Traditional epoprostenol formulation	Improved stability profile	Different molecule and longer half-life
Excipient opportunity	Reconstitution and stability improvement	Product-specific stability and device claims	Delivery-system and route differentiation
Biosimilar pathway	Not applicable	Not applicable	Not applicable
Main commercial threat	Generic epoprostenol and alternative prostacyclin therapy	Generic and alternative prostacyclin therapy	Broader route and convenience advantages

Flolan has the weakest differentiation when evaluated only on excipients. A new product needs a measurable operational benefit, such as fewer preparation steps, longer room-temperature stability, lower waste, or improved device compatibility.

What geographic opportunities exist for Flolan excipient products?

The United States and Europe have the strongest regulatory and hospital infrastructure for specialty pulmonary hypertension products. Japan and other regulated markets may offer opportunities where injectable prostacyclin supply is concentrated among a small number of manufacturers.

Emerging markets may prioritize:

• Ambient-temperature stability.
• Lower-cost excipients.
• Simplified reconstitution.
• Reduced refrigeration.
• Local sterile manufacturing.
• Longer shelf life under transport conditions.

Geographic expansion requires separate evaluation of pharmacopoeial standards, excipient monographs, local stability zones, language requirements, and reliance on local contract manufacturing. A formulation designed for temperate-zone storage may not be suitable for hot and humid markets without additional stability data.

Key Takeaways

• Flolan contains epoprostenol sodium with glycine, mannitol, and sodium hydroxide in a lyophilized injectable formulation.
• The principal technical problem is aqueous instability, not active-ingredient discovery.
• Original compound and regulatory exclusivity are no longer the main barriers to competition.
• Biosimilar regulation does not apply; generic and 505(b)(2) pathways are more relevant.
• The strongest commercial opportunity is a stable, simplified, ready-to-use or premixed presentation.
• Excipient patents should be tied to measurable stability, handling, packaging, or delivery benefits.
• Veletri demonstrates the commercial value of formulation and stability differentiation.
• Generic launch risk is high, but sterile manufacturing and supply reliability remain meaningful barriers.
• The most attractive supplier opportunities involve validated parenteral excipients, lyophilization, packaging, tubing, and contract sterile manufacturing.

FAQs

Can mannitol be replaced in a Flolan formulation?

Potentially, but replacement would require evidence covering lyophilized cake quality, reconstitution, osmolality, chemical stability, particulate levels, and container compatibility. Mannitol is a conventional excipient, so a replacement would need a clear technical advantage to support differentiated intellectual property.

Is a ready-to-use epoprostenol product commercially attractive?

Yes. A ready-to-use format could reduce pharmacy preparation, cold-chain requirements, dosing errors, and waste. Its commercial value depends on maintaining potency and impurity control through shelf life and administration.

Does Flolan have biosimilar competition?

No. Epoprostenol sodium is a chemically synthesized small molecule. Competitors use generic or alternative NDA pathways rather than the FDA biosimilar pathway.

What is the most important excipient-related patent risk?

The key risk is a later formulation patent claiming a specific excipient combination, pH range, concentration, stability period, or container system. Broad claims covering glycine or mannitol alone are less likely to provide durable exclusivity.

Could a higher-concentration epoprostenol product replace Flolan?

It could compete in selected patients if it reduces infusion volume and maintains dosing flexibility. Adoption would depend on pump compatibility, clinical conversion protocols, stability, and the risk of concentration-related medication errors.

References

1. GlaxoSmithKline. (2010). Flolan (epoprostenol sodium) for injection prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (1995). Approval letter and prescribing information for Flolan (epoprostenol sodium). Drugs@FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. Actelion Pharmaceuticals US, Inc. (2010). Veletri (epoprostenol sodium) for injection prescribing information. U.S. Food and Drug Administration.